<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408377</article-id><article-id pub-id-type="pmc">PMC12101704</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0324027</article-id><article-id pub-id-type="publisher-id">PONE-D-25-04360</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Blood Pressure</subject><subj-group><subject>Hypertension</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Cardiovascular Diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Cardiovascular Medicine</subject><subj-group><subject>Cardiovascular Diseases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Inflammatory Diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Albumins</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Relationship between the ratio of erythrocyte distribution width to albumin level and mortality in hypertensive population: Mediating role of inflammatory markers</article-title><alt-title alt-title-type="running-head">RAR and mortality</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Huang</surname><given-names>Dongli</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zou</surname><given-names>Chun</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-6158-0748</contrib-id><name><surname>Wu</surname><given-names>Hang</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="cor001" ref-type="corresp">*</xref><xref rid="aff001" ref-type="aff"/></contrib></contrib-group><aff id="aff001">
<addr-line>Bishan Hospital of Chongqing Medical University, Chongqing, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Wu</surname><given-names>Jian</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Duke University Medical Center: Duke University Hospital, UNITED STATES OF AMERICA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>wuhang0613@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0324027</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Huang et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Huang et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0324027.pdf">
</self-uri><abstract><sec id="sec001"><title>Background</title><p>This study examined the ratio of erythrocyte distribution width (RDW) to albumin concentration (RAR) and all-cause, cardiovascular disease (CVD), and cancer mortality in the hypertension population, focusing on the role of inflammatory markers as mediators.</p></sec><sec id="sec002"><title>Patients and methods</title><p>Data from NHANES (1999&#x02013;2018) were analyzed, linking National Death Index (NDI) records to mortality outcomes through December 31, 2019. A weighted sampling design categorized participants into three RAR groups. Cox regression models adjusted for demographic and clinical variables assessed the association between RAR and mortality outcomes. Mediation analyses explored the mediating role of the systemic Inflammatory response index (SIRI) and neutrophil-to-lymphocyte ratio (NLR).</p></sec><sec id="sec003"><title>Results</title><p>Among 26,935 participants with a median follow-up of 102 months and 6,007 deaths, elevated RAR was associated with increased risks of all-cause mortality (HR&#x02009;=&#x02009;1.83, 95% CI: 1.76&#x02013;1.90), cardiovascular disease mortality (HR&#x02009;=&#x02009;1.81, 95% CI: 1.68&#x02013;1.95), and cancer mortality (HR&#x02009;=&#x02009;1.70, 95% CI: 1.55&#x02013;1.86). Segmented regression showed a nonlinear relationship between RAR and all-cause mortality, cardiovascular mortality, and cancer mortality, and the threshold effect results showed a fold value of 4.10, with a greater HR when RAR&#x02009;&#x0003c;&#x02009;4.10. Mediation analysis revealed that SIRI and NLR mediated the relationship between RAR and all-cause mortality by 8.12% and 6.00%, respectively.</p></sec><sec id="sec004"><title>Conclusion</title><p>In hypertensive populations, higher RAR values are associated with increased all-cause mortality, cardiovascular mortality, and cancer mortality. Inflammation partially mediates the relationship between RAR and all-cause mortality.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Bishan Hospital of Chongqing Medical University</institution>
</funding-source><award-id>BYKY-CX2024014</award-id><principal-award-recipient>
<name><surname>Huang</surname><given-names>Dongli</given-names></name>
</principal-award-recipient></award-group><funding-statement>Our study obtained Scientific Research and Innovation Team Project of the Affiliated Bishan Hospital of Chongqing Medical University (Bishan District People's Hospital, Chongqing) (Project Number: BYKY-CX2024014).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The data of this study are publicly available for free from the NHANES database (<ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/</ext-link>). The dataset used for our analysis can be found in <xref rid="pone.0324027.s001" ref-type="supplementary-material">S1 Raw data</xref>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The data of this study are publicly available for free from the NHANES database (<ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/</ext-link>). The dataset used for our analysis can be found in <xref rid="pone.0324027.s001" ref-type="supplementary-material">S1 Raw data</xref>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Hypertension is a global epidemic, currently affecting approximately 1.13 billion people [<xref rid="pone.0324027.ref001" ref-type="bibr">1</xref>]. Individuals with hypertension are at a significantly higher risk of death compared to the general population, with hypertension being a leading cause of death worldwide, accounting for approximately 9.4 million deaths annually [<xref rid="pone.0324027.ref002" ref-type="bibr">2</xref>]. Thus, identifying prognostic indicators that can pinpoint high-risk individuals is crucial for improving clinical outcomes in hypertensive patients [<xref rid="pone.0324027.ref003" ref-type="bibr">3</xref>].</p><p>In recent years, erythrocyte distribution width (RDW) and albumin (ALB) have gained significant clinical attention as important biomarkers. RDW reflects erythrocyte volume variability, serving as a sensitive indicator closely related to the onset and prognosis of various chronic diseases, such as cardiovascular disease, diabetes mellitus, and chronic kidney disease [<xref rid="pone.0324027.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0324027.ref006" ref-type="bibr">6</xref>]. Albumin, the major plasma protein, plays a critical role in maintaining colloid osmotic pressure and reflects the body&#x02019;s nutritional status. Low albumin levels are commonly associated with chronic inflammation, malnutrition, and disease progression, which contribute to a poor prognosis. As a composite biomarker, RAR effectively reflects various physiological states, including chronic inflammation, oxidative stress, and malnutrition. Hao et al. found that high RAR was strongly associated with mortality in the general population [<xref rid="pone.0324027.ref007" ref-type="bibr">7</xref>]. Other studies have explored its association with mortality in specific populations, particularly those with chronic inflammatory conditions such as rheumatoid arthritis, diabetes mellitus, and diabetic retinopathy [<xref rid="pone.0324027.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0324027.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0324027.ref009" ref-type="bibr">9</xref>]. However, the association between RAR and prognosis in hypertensive patients remains underexplored. Therefore, this study aimed to investigate the relationship between RAR and prognosis in hypertensive patients and explore the role of inflammation in this process.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Data and study participants</title><p>The National Health and Nutrition Examination Survey (NHANES) is a population-based study designed to collect health and nutritional data from a representative sample of the U.S. household population. Data were obtained through a multistage probability sampling approach, encompassing structured household interviews, physical examinations conducted at mobile examination centers, and laboratory assessments. This study utilized de-identified data from NHANES, a publicly accessible database managed by the National Center for Health Statistics (NCHS), a division of the Centers for Disease Control and Prevention (CDC). The NHANES data collection protocol was approved by the NCHS Research Ethics Review Board (ERB). Given that this study involved secondary analysis of anonymized, publicly available data, it was exempt from additional Institutional Review Board (IRB) review. Informed consent was obtained from all NHANES participants by the NCHS during the original data collection, and no further consent was required for this analysis. A total of 30,990 hypertensive patients were identified from the NHANES 1999&#x02013;2018 dataset. Specifically, based on NHANES database information, hypertension was defined as systolic blood pressure &#x02265;130 mmHg, diastolic blood pressure &#x02265;80 mmHg, a physician diagnosis of high blood pressure, or current use of prescription medication for hypertension. We excluded 3,124 individuals missing RDW or albumin (Alb) values required for the RAR formula. Additionally, 755 respondents were excluded due to missing final survival status data. To ensure result reliability, 176 pregnant women were excluded. The complete data screening process is illustrated in <xref rid="pone.0324027.g001" ref-type="fig">Fig 1</xref>. All data used in this study were publicly available (<ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/</ext-link>) and were weighted based on demographic characteristics for subsequent analysis.</p><fig position="float" id="pone.0324027.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.g001</object-id><label>Fig 1</label><caption><title>Flowchart of the study population.</title></caption><graphic xlink:href="pone.0324027.g001" position="float"/></fig></sec><sec id="sec008"><title>Definition of the ratio of erythrocyte distribution width to albumin index</title><p>In the NHANES study, serum albumin concentration was measured using the bromocresol purple method.RDW was measured using a Coulter analyzer in mobile examination centers with peripheral blood samples. RAR was calculated using the formula RDW/Alb, as described in previous studies [<xref rid="pone.0324027.ref010" ref-type="bibr">10</xref>].</p></sec><sec id="sec009"><title>Definition of the the systemic inflammatory response index and the neutrophil&#x02013;lymphocyte ratio</title><p>Neutrophil, lymphocyte, and monocyte counts were measured using automated hematology analyzers.The systemic Inflammatory response index (SIRI) is calculated as: SIRI = (Monocyte count&#x02009;&#x000d7;&#x02009;Neutrophil count)/ Lymphocyte count. The neutrophil&#x02013;lymphocyte ratio (NLR) is calculated as: NLR&#x02009;=&#x02009;Neutrophil count/ Lymphocyte count.</p></sec><sec id="sec010"><title>Outcome ascertainment</title><p>All-cause mortality was assessed using National Death Index (NDI) records linked to the NHANES dataset, with follow-up data available through December 31, 2019. Cause-specific mortality was classified based on ICD-10 codes. Cardiovascular disease (CVD) mortality was defined by ICD-10 codes I00&#x02013;I09, I11, I13, and I20&#x02013;I51. Cancer mortality was defined by ICD-10 codes C00&#x02013;C97.</p></sec><sec id="sec011"><title>Assessment of covariates</title><p>The covariates in this study included age(&#x0003c;45,45&#x02013;60,&#x02009;&#x0003e;60), gender, race, education level, marital status, household poverty-to-income ratio (PIR), body mass index (BMI), physical activity (vigorous or moderate), smoking status, alcohol consumption, diabetes mellitus, hypercholesterolemia, and cardiovascular disease (CVD). Physical activity was categorized as vigorous (yes/no) or moderate (yes/no). Participants who reported smoking at least 100 cigarettes in their lifetime and continued smoking at the time of the survey were defined as current smokers. Former smokers were defined as individuals who had smoked at least 100 cigarettes in their lifetime but had quit smoking by the time of the survey. Additionally, individuals who had smoked fewer than 100 cigarettes in their lifetime were classified as nonsmokers. Nondrinkers were participants who reported not consuming at least 12 alcoholic beverages in their lifetime or any given year. In this study, individuals who reported consuming 12 alcoholic beverages in their lifetime or within any year but abstained from alcohol in the past 12 months were classified as former drinkers. Participants who reported consuming 12 alcoholic beverages in their lifetime or any year and drank at least one alcoholic beverage in the past 12 months were defined as current drinkers. Participants were considered diabetic if they had been diagnosed by a physician, had a fasting blood glucose level &#x02265;7.0 mmol/L, glycosylated hemoglobin &#x02265;6.5%, a 75&#x02009;g oral glucose tolerance test result &#x02265;200&#x02009;mg/dL, or were using glucose-lowering medications or insulin. Hypercholesterolemia was defined as total cholesterol &#x0003e;5.2 mmol/L, low-density lipoprotein cholesterol (LDL-C) &#x0003e;3.4 mmol/L, or the use of lipid-lowering medications. CVD was defined as a prior diagnosis of congestive heart failure, coronary artery disease, angina, stroke, or myocardial infarction.</p></sec><sec id="sec012"><title>Statistical analysis</title><p>All statistical analyses in this study accounted for the multi-stage NHANES design by incorporating appropriate sampling weights, strata, and primary sampling units. In the baseline characteristics table, continuous variables were presented as weighted means with standard errors (SE), and categorical variables as weighted proportions. The Kruskal-Wallis rank sum test was applied to continuous variables, and the survey-weighted chi-square test was used for categorical variables, to evaluate differences across RAR tertiles. Multivariate Cox regression was employed to examine the relationship between RAR and all-cause, cardiovascular disease, and cancer mortality. Three models were employed: Model 1 (unadjusted); Model 2 (adjusted for age, sex, and ethnicity); and Model 3 (adjusted for age, sex, ethnicity, body mass index, education, marital status, PIR, hypercholesterolemia, diabetes mellitus, alcohol consumption, physical activity, cardiovascular disease, and smoking). We applied smoothed curve fitting and generalized additive modeling (GAM) to examine the nonlinear association between RAR and all-cause and cause-specific mortality. When nonlinear correlations were detected, we fitted a two-stage linear regression model (segmented regression) to each interval to assess threshold effects. The breakpoint (K) was identified using a two-step recursive method (<xref rid="pone.0324027.s002" ref-type="supplementary-material">S1 File</xref>). Mediation analyses were conducted to explore the potential mediating roles of two inflammatory markers (SIRI and NLR) in the relationship between RAR and all-cause mortality, adjusting for factors in the primary analysis Model 3.All statistical analyses were conducted using EmpowerStats (<ext-link xlink:href="http://www.empowerstats.com" ext-link-type="uri">http://www.empowerstats.com</ext-link>, X&#x00026;Y Solutions, Inc.) and R statistical software (<ext-link xlink:href="http://www.R-project.org" ext-link-type="uri">http://www.R-project.org</ext-link>; The R Foundation).</p></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Association between RAR and mortality</title><p>As shown in <xref rid="pone.0324027.t001" ref-type="table">Table 1</xref>, the study included 26,935 participants aged 18 years or older, with 52.72% being male. The all-cause mortality rate was 22.30% over a median follow-up of 102 months. Baseline characteristics for each RAR stratum are presented in <xref rid="pone.0324027.t001" ref-type="table">Table 1</xref>. Participants with higher RAR levels were more likely to be over 60 years old and to have diabetes or cardiovascular disease.</p><table-wrap position="float" id="pone.0324027.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of NHANES participants from 1999-2018. Classified according to RAR tertiles.</title></caption><alternatives><graphic xlink:href="pone.0324027.t001" id="pone.0324027.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="left" colspan="3" rowspan="1">Tertiles of RAR</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P value</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">T1</th><th align="left" rowspan="1" colspan="1">T2</th><th align="left" rowspan="1" colspan="1">T3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">8949</td><td align="left" rowspan="1" colspan="1">8991</td><td align="left" rowspan="1" colspan="1">8995</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up time,(months)</td><td align="left" rowspan="1" colspan="1">138.80&#x02009;&#x000b1;&#x02009;63.28</td><td align="left" rowspan="1" colspan="1">108.26&#x02009;&#x000b1;&#x02009;61.39</td><td align="left" rowspan="1" colspan="1">82.08&#x02009;&#x000b1;&#x02009;58.22</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">51.00&#x02009;&#x000b1;&#x02009;17.47</td><td align="left" rowspan="1" colspan="1">58.57&#x02009;&#x000b1;&#x02009;16.21</td><td align="left" rowspan="1" colspan="1">60.55&#x02009;&#x000b1;&#x02009;15.70</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SII</td><td align="left" rowspan="1" colspan="1">540.74&#x02009;&#x000b1;&#x02009;313.52</td><td align="left" rowspan="1" colspan="1">537.34&#x02009;&#x000b1;&#x02009;314.38</td><td align="left" rowspan="1" colspan="1">614.82&#x02009;&#x000b1;&#x02009;563.56</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SIRI</td><td align="left" rowspan="1" colspan="1">1.22&#x02009;&#x000b1;&#x02009;0.80</td><td align="left" rowspan="1" colspan="1">1.27&#x02009;&#x000b1;&#x02009;0.86</td><td align="left" rowspan="1" colspan="1">1.45&#x02009;&#x000b1;&#x02009;1.19</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">NLR</td><td align="left" rowspan="1" colspan="1">2.15&#x02009;&#x000b1;&#x02009;1.09</td><td align="left" rowspan="1" colspan="1">2.18&#x02009;&#x000b1;&#x02009;1.13</td><td align="left" rowspan="1" colspan="1">2.41&#x02009;&#x000b1;&#x02009;1.57</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PLR</td><td align="left" rowspan="1" colspan="1">128.65&#x02009;&#x000b1;&#x02009;48.69</td><td align="left" rowspan="1" colspan="1">126.80&#x02009;&#x000b1;&#x02009;50.38</td><td align="left" rowspan="1" colspan="1">135.00&#x02009;&#x000b1;&#x02009;65.57</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PPN</td><td align="left" rowspan="1" colspan="1">1079.10&#x02009;&#x000b1;&#x02009;551.38</td><td align="left" rowspan="1" colspan="1">1071.73&#x02009;&#x000b1;&#x02009;578.94</td><td align="left" rowspan="1" colspan="1">1176.72&#x02009;&#x000b1;&#x02009;1142.80</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR</td><td align="left" rowspan="1" colspan="1">2.75&#x02009;&#x000b1;&#x02009;0.14</td><td align="left" rowspan="1" colspan="1">3.10&#x02009;&#x000b1;&#x02009;0.10</td><td align="left" rowspan="1" colspan="1">3.72&#x02009;&#x000b1;&#x02009;0.51</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL, (mmol/L)</td><td align="left" rowspan="1" colspan="1">3.14&#x02009;&#x000b1;&#x02009;0.92</td><td align="left" rowspan="1" colspan="1">3.02&#x02009;&#x000b1;&#x02009;0.95</td><td align="left" rowspan="1" colspan="1">2.85&#x02009;&#x000b1;&#x02009;0.95</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL, (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.34&#x02009;&#x000b1;&#x02009;0.42</td><td align="left" rowspan="1" colspan="1">1.35&#x02009;&#x000b1;&#x02009;0.42</td><td align="left" rowspan="1" colspan="1">1.35&#x02009;&#x000b1;&#x02009;0.43</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">TC, (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.30&#x02009;&#x000b1;&#x02009;1.10</td><td align="left" rowspan="1" colspan="1">5.16&#x02009;&#x000b1;&#x02009;1.10</td><td align="left" rowspan="1" colspan="1">4.91&#x02009;&#x000b1;&#x02009;1.13</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">TG, (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.75&#x02009;&#x000b1;&#x02009;1.33</td><td align="left" rowspan="1" colspan="1">1.65&#x02009;&#x000b1;&#x02009;1.23</td><td align="left" rowspan="1" colspan="1">1.48&#x02009;&#x000b1;&#x02009;1.30</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">All-cause mortality</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">7418 (82.89%)</td><td align="left" rowspan="1" colspan="1">6948 (77.28%)</td><td align="left" rowspan="1" colspan="1">6562 (72.95%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">1531 (17.11%)</td><td align="left" rowspan="1" colspan="1">2043 (22.72%)</td><td align="left" rowspan="1" colspan="1">2433 (27.05%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular mortality</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">8567 (95.73%)</td><td align="left" rowspan="1" colspan="1">8464 (94.14%)</td><td align="left" rowspan="1" colspan="1">8288 (92.14%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">382 (4.27%)</td><td align="left" rowspan="1" colspan="1">527 (5.86%)</td><td align="left" rowspan="1" colspan="1">707 (7.86%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cancer mortality</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">8603 (96.13%)</td><td align="left" rowspan="1" colspan="1">8531 (94.88%)</td><td align="left" rowspan="1" colspan="1">8555 (95.11%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">346 (3.87%)</td><td align="left" rowspan="1" colspan="1">460 (5.12%)</td><td align="left" rowspan="1" colspan="1">440 (4.89%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">5761 (64.38%)</td><td align="left" rowspan="1" colspan="1">4688 (52.14%)</td><td align="left" rowspan="1" colspan="1">3750 (41.69%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">3188 (35.62%)</td><td align="left" rowspan="1" colspan="1">4303 (47.86%)</td><td align="left" rowspan="1" colspan="1">5245 (58.31%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age,n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;45</td><td align="left" rowspan="1" colspan="1">3294 (36.81%)</td><td align="left" rowspan="1" colspan="1">1853 (20.61%)</td><td align="left" rowspan="1" colspan="1">1574 (17.50%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=45,&#x02009;&#x0003c;&#x02009;60</td><td align="left" rowspan="1" colspan="1">2418 (27.02%)</td><td align="left" rowspan="1" colspan="1">2325 (25.86%)</td><td align="left" rowspan="1" colspan="1">2167 (24.09%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=60</td><td align="left" rowspan="1" colspan="1">3237 (36.17%)</td><td align="left" rowspan="1" colspan="1">4813 (53.53%)</td><td align="left" rowspan="1" colspan="1">5254 (58.41%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PIR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;1.3</td><td align="left" rowspan="1" colspan="1">2213 (24.73%)</td><td align="left" rowspan="1" colspan="1">2414 (26.85%)</td><td align="left" rowspan="1" colspan="1">2947 (32.76%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=1.3,&#x02009;&#x0003c;&#x02009;3.5</td><td align="left" rowspan="1" colspan="1">3796 (42.42%)</td><td align="left" rowspan="1" colspan="1">4050 (45.05%)</td><td align="left" rowspan="1" colspan="1">4138 (46.00%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=3.5</td><td align="left" rowspan="1" colspan="1">2940 (32.85%)</td><td align="left" rowspan="1" colspan="1">2527 (28.11%)</td><td align="left" rowspan="1" colspan="1">1910 (21.23%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">2487 (27.79%)</td><td align="left" rowspan="1" colspan="1">1899 (21.12%)</td><td align="left" rowspan="1" colspan="1">1573 (17.49%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=25,&#x02009;&#x0003c;&#x02009;30</td><td align="left" rowspan="1" colspan="1">3648 (40.76%)</td><td align="left" rowspan="1" colspan="1">3240 (36.04%)</td><td align="left" rowspan="1" colspan="1">2612 (29.04%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;=30</td><td align="left" rowspan="1" colspan="1">2814 (31.44%)</td><td align="left" rowspan="1" colspan="1">3852 (42.84%)</td><td align="left" rowspan="1" colspan="1">4810 (53.47%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Mexican American</td><td align="left" rowspan="1" colspan="1">1696 (18.95%)</td><td align="left" rowspan="1" colspan="1">1394 (15.50%)</td><td align="left" rowspan="1" colspan="1">1099 (12.22%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other Hispanic</td><td align="left" rowspan="1" colspan="1">600 (6.70%)</td><td align="left" rowspan="1" colspan="1">765 (8.51%)</td><td align="left" rowspan="1" colspan="1">663 (7.37%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-Hispanic White</td><td align="left" rowspan="1" colspan="1">4691 (52.42%)</td><td align="left" rowspan="1" colspan="1">4190 (46.60%)</td><td align="left" rowspan="1" colspan="1">3333 (37.05%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="left" rowspan="1" colspan="1">1185 (13.24%)</td><td align="left" rowspan="1" colspan="1">1896 (21.09%)</td><td align="left" rowspan="1" colspan="1">3206 (35.64%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other Race</td><td align="left" rowspan="1" colspan="1">777 (8.68%)</td><td align="left" rowspan="1" colspan="1">746 (8.30%)</td><td align="left" rowspan="1" colspan="1">694 (7.72%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Under high school</td><td align="left" rowspan="1" colspan="1">2330 (26.04%)</td><td align="left" rowspan="1" colspan="1">2609 (29.02%)</td><td align="left" rowspan="1" colspan="1">2789 (31.01%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">High school or equivalent</td><td align="left" rowspan="1" colspan="1">2047 (22.87%)</td><td align="left" rowspan="1" colspan="1">2207 (24.55%)</td><td align="left" rowspan="1" colspan="1">2175 (24.18%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">College graduate or above</td><td align="left" rowspan="1" colspan="1">4572 (51.09%)</td><td align="left" rowspan="1" colspan="1">4175 (46.44%)</td><td align="left" rowspan="1" colspan="1">4031 (44.81%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Marital Status, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Married or living with partner</td><td align="left" rowspan="1" colspan="1">5877 (65.67%)</td><td align="left" rowspan="1" colspan="1">5550 (61.73%)</td><td align="left" rowspan="1" colspan="1">4706 (52.32%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">living alone</td><td align="left" rowspan="1" colspan="1">3072 (34.33%)</td><td align="left" rowspan="1" colspan="1">3441 (38.27%)</td><td align="left" rowspan="1" colspan="1">4289 (47.68%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoke, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smokers</td><td align="left" rowspan="1" colspan="1">1638 (18.30%)</td><td align="left" rowspan="1" colspan="1">1672 (18.60%)</td><td align="left" rowspan="1" colspan="1">1794 (19.94%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nonsmokers</td><td align="left" rowspan="1" colspan="1">4722 (52.77%)</td><td align="left" rowspan="1" colspan="1">4665 (51.89%)</td><td align="left" rowspan="1" colspan="1">4579 (50.91%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Former smokers</td><td align="left" rowspan="1" colspan="1">2589 (28.93%)</td><td align="left" rowspan="1" colspan="1">2654 (29.52%)</td><td align="left" rowspan="1" colspan="1">2622 (29.15%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">7520 (84.03%)</td><td align="left" rowspan="1" colspan="1">6810 (75.74%)</td><td align="left" rowspan="1" colspan="1">5877 (65.34%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">1429 (15.97%)</td><td align="left" rowspan="1" colspan="1">2181 (24.26%)</td><td align="left" rowspan="1" colspan="1">3118 (34.66%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Vigorous activity, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">5722 (63.94%)</td><td align="left" rowspan="1" colspan="1">6597 (73.37%)</td><td align="left" rowspan="1" colspan="1">7182 (79.84%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">3227 (36.06%)</td><td align="left" rowspan="1" colspan="1">2394 (26.63%)</td><td align="left" rowspan="1" colspan="1">1813 (20.16%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate activity, (n%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">4929 (55.08%)</td><td align="left" rowspan="1" colspan="1">5466 (60.79%)</td><td align="left" rowspan="1" colspan="1">6072 (67.50%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">4020 (44.92%)</td><td align="left" rowspan="1" colspan="1">3525 (39.21%)</td><td align="left" rowspan="1" colspan="1">2923 (32.50%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Drink, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Current drinkers</td><td align="left" rowspan="1" colspan="1">6484 (72.46%)</td><td align="left" rowspan="1" colspan="1">5739 (63.83%)</td><td align="left" rowspan="1" colspan="1">5209 (57.91%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nondrinkers</td><td align="left" rowspan="1" colspan="1">975 (10.90%)</td><td align="left" rowspan="1" colspan="1">1290 (14.35%)</td><td align="left" rowspan="1" colspan="1">1393 (15.49%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Former drinkers</td><td align="left" rowspan="1" colspan="1">1490 (16.65%)</td><td align="left" rowspan="1" colspan="1">1962 (21.82%)</td><td align="left" rowspan="1" colspan="1">2393 (26.60%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CVD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">8071 (90.19%)</td><td align="left" rowspan="1" colspan="1">7513 (83.56%)</td><td align="left" rowspan="1" colspan="1">6829 (75.92%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">878 (9.81%)</td><td align="left" rowspan="1" colspan="1">1478 (16.44%)</td><td align="left" rowspan="1" colspan="1">2166 (24.08%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia, n(%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">2829 (31.61%)</td><td align="left" rowspan="1" colspan="1">3223 (35.85%)</td><td align="left" rowspan="1" colspan="1">3823 (42.50%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">6120 (68.39%)</td><td align="left" rowspan="1" colspan="1">5768 (64.15%)</td><td align="left" rowspan="1" colspan="1">5172 (57.50%)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>RAR Erythrocyte distribution width to albumin ratio, PIR poverty-to-income ratio, BMI body mass index, SII systemic immune-inflammation index, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec015"><title>Association between RAR and mortality</title><p>As shown in <xref rid="pone.0324027.t002" ref-type="table">Table 2</xref>, higher RAR levels were significantly associated with an increased risk of all-cause mortality in Model 1 (HR&#x02009;=&#x02009;2.08, 95% CI: 2.01&#x02013;2.15). The association remained robust and statistically significant after multivariate adjustments in Model 2 (HR&#x02009;=&#x02009;2.06, 95% CI: 1.99&#x02013;2.13) and Model 3 (HR&#x02009;=&#x02009;1.83, 95% CI: 1.76&#x02013;1.90). Participants were categorized into three groups according to RAR tertiles. Compared with the first tertile, participants in the third tertile exhibited a 119% increase in all-cause mortality, a 125% increase in cardiovascular mortality, and a 78% increase in cancer mortality. The trend across tertiles was statistically significant (trend p&#x02009;&#x0003c;&#x02009;0.0001).</p><table-wrap position="float" id="pone.0324027.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.t002</object-id><label>Table 2</label><caption><title>Association of RAR with mortality in the population.</title></caption><alternatives><graphic xlink:href="pone.0324027.t002" id="pone.0324027.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" rowspan="1" colspan="1">Model 1</th><th align="left" rowspan="1" colspan="1">Model 2</th><th align="left" rowspan="1" colspan="1">Model 3</th></tr><tr><th align="left" rowspan="1" colspan="1">HR 95% CI</th><th align="left" rowspan="1" colspan="1">HR 95% CI</th><th align="left" rowspan="1" colspan="1">HR 95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>All-cause mortality</bold>
</td><td align="left" rowspan="1" colspan="1">2.08 (2.01, 2.15)</td><td align="left" rowspan="1" colspan="1">2.06 (1.99, 2.13)</td><td align="left" rowspan="1" colspan="1">1.83 (1.76, 1.90)</td></tr><tr><td align="left" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">T2</td><td align="left" rowspan="1" colspan="1">1.83 (1.71, 1.96)</td><td align="left" rowspan="1" colspan="1">1.44 (1.35, 1.54)</td><td align="left" rowspan="1" colspan="1">1.34 (1.25, 1.44)</td></tr><tr><td align="left" rowspan="1" colspan="1">T3</td><td align="left" rowspan="1" colspan="1">3.07 (2.88, 3.28)</td><td align="left" rowspan="1" colspan="1">2.63 (2.46, 2.82)</td><td align="left" rowspan="1" colspan="1">2.19 (2.04, 2.35)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cardiovascular mortality</bold>
</td><td align="left" rowspan="1" colspan="1">2.12 (2.00, 2.25)</td><td align="left" rowspan="1" colspan="1">2.08 (1.96, 2.22)</td><td align="left" rowspan="1" colspan="1">1.81 (1.68, 1.95)</td></tr><tr><td align="left" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">T2</td><td align="left" rowspan="1" colspan="1">1.89 (1.66, 2.16)</td><td align="left" rowspan="1" colspan="1">1.47 (1.29, 1.68)</td><td align="left" rowspan="1" colspan="1">1.33 (1.16, 1.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">T3</td><td align="left" rowspan="1" colspan="1">3.57 (3.14, 4.05)</td><td align="left" rowspan="1" colspan="1">2.99 (2.62, 3.42)</td><td align="left" rowspan="1" colspan="1">2.25 (1.96, 2.58)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cancer Mortality</bold>
</td><td align="left" rowspan="1" colspan="1">1.89 (1.74, 2.04)</td><td align="left" rowspan="1" colspan="1">1.85 (1.70, 2.02)</td><td align="left" rowspan="1" colspan="1">1.70 (1.55, 1.86)</td></tr><tr><td align="left" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" rowspan="1" colspan="1">T2</td><td align="left" rowspan="1" colspan="1">1.78 (1.55, 2.05)</td><td align="left" rowspan="1" colspan="1">1.43 (1.24, 1.65)</td><td align="left" rowspan="1" colspan="1">1.36 (1.18, 1.57)</td></tr><tr><td align="left" rowspan="1" colspan="1">T3</td><td align="left" rowspan="1" colspan="1">2.37 (2.05, 2.73)</td><td align="left" rowspan="1" colspan="1">2.02 (1.74, 2.35)</td><td align="left" rowspan="1" colspan="1">1.78 (1.53, 2.08)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>HR: hazard ratio.</p></fn><fn id="t002fn002"><p>95% CI: 95% confidence interval.</p></fn><fn id="t002fn003"><p>Model 1: no covariates were adjusted.</p></fn><fn id="t002fn004"><p>Model 2: Adjusted for age, gender, and race.</p></fn><fn id="t002fn005"><p>Model 3: Age, gender, race, body mass index, education, marital status, PIR, diabetes, alcohol consumption, vigorous activity, moderate activity, cardiovascular disease, smoking, hyper cholesterol.</p></fn></table-wrap-foot></table-wrap><p>The Kaplan-Meier curve (<xref rid="pone.0324027.g002" ref-type="fig">Fig 2</xref>) supports these findings. The curve illustrates that in the hypertensive population, participants with higher RAR levels experienced a greater decline in survival during follow-up compared with those with lower RAR levels (log-rank p&#x02009;&#x0003c;&#x02009;0.05). <xref rid="pone.0324027.g003" ref-type="fig">Fig 3</xref> demonstrates that after full adjustment for confounders and smooth curve fitting, a positive association was observed between RAR and all-cause, cardiovascular, and cancer mortality. Threshold effects analysis showed that HR was greater when the RAR was less than 4.1 (<xref rid="pone.0324027.t003" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="pone.0324027.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.t003</object-id><label>Table 3</label><caption><title>Threshold effects of RAR on mortality analyzed using linear regression models.</title></caption><alternatives><graphic xlink:href="pone.0324027.t003" id="pone.0324027.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI), P Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>RAR vs All-cause mortality</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the standard linear model</td><td align="left" rowspan="1" colspan="1">1.82(1.76, 1.89) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the two-piecewise linear model</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RAR</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Inflection point</td><td align="left" rowspan="1" colspan="1">4.10</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003c;&#x02009;4.10</td><td align="left" rowspan="1" colspan="1">2.47(2.30, 2.65) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003e;4.10<break/>Log likelihood ratio</td><td align="left" rowspan="1" colspan="1">1.35(1.24, 1.47) &#x0003c;0.0001<break/>&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RAR vs CVD mortality</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the standard linear model</td><td align="left" rowspan="1" colspan="1">1.81(1.68, 1.95) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the two-piecewise linear model</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RAR</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Inflection point</td><td align="left" rowspan="1" colspan="1">4.10</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003c;&#x02009;4.10</td><td align="left" rowspan="1" colspan="1">2.44(2.12, 2.79) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003e;4.10<break/>Log likelihood ratio</td><td align="left" rowspan="1" colspan="1">1.31(1.10, 1.56) 0.0029<break/>&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RAR vs cancer mortality</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the standard linear model</td><td align="left" rowspan="1" colspan="1">1.69(1.54, 1.85) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fitting by the two-piecewise linear model</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RAR</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Inflection point</td><td align="left" rowspan="1" colspan="1">4.10</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003c;&#x02009;4.10</td><td align="left" rowspan="1" colspan="1">1.97(1.68, 2.32) &#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RAR&#x02009;&#x0003e;4.10</td><td align="left" rowspan="1" colspan="1">1.42(1.18, 1.72) 0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">Log likelihood ratio</td><td align="left" rowspan="1" colspan="1">0.0019</td></tr></tbody></table></alternatives></table-wrap><fig position="float" id="pone.0324027.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.g002</object-id><label>Fig 2</label><caption><title>Kaplan-Meier survival curves for the effect of RAR on long-term all-cause(A) and cardiovascular disease(B), and cancer(C) mortality in the hypertension population.</title></caption><graphic xlink:href="pone.0324027.g002" position="float"/></fig><fig position="float" id="pone.0324027.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.g003</object-id><label>Fig 3</label><caption><title>Association between RAR and hypertension population-based all-cause mortality (A), cardiovascular disease (B), and cancer (C) mortality.</title><p>Adjustments have been made for age, sex, race, body mass index, education, marital status, PIR, hypercholesterolemia, diabetes mellitus, alcohol consumption, vigorous activity, moderate activity, cardiovascular disease, and smoking.</p></caption><graphic xlink:href="pone.0324027.g003" position="float"/></fig></sec><sec id="sec016"><title>Sensitivity analysis</title><p>We incorporated age as a continuous covariate in the Cox regression analyses, which revealed (<xref rid="pone.0324027.s001" ref-type="supplementary-material">S1 Table</xref>) no substantial change in study outcomes, with HR values showing consistent effect directions and variations within 3%. Age-stratified analyses revealed that, among hypertensive patients, RAR and mortality exhibited consistent associations with statistically significant P-values across all age groups (&#x0003c;45, 45&#x02013;60,&#x02009;&#x0003e;&#x02009;60 years) (<xref rid="pone.0324027.s004" ref-type="supplementary-material">S2 Table</xref>).</p></sec><sec id="sec017"><title>The mediating role of SII and SIRI</title><p>High levels of RAR are associated with increased all-cause mortality. To investigate the mediating role of inflammation in the relationship between RAR and all-cause mortality among a hypertensive population, we conducted mediation analyses using SIRI and NLR as markers of systemic inflammatory status. In the fully adjusted model, RAR was correlated with SIRI (&#x003b2;&#x02009;=&#x02009;0.34, 95% CI: 0.32&#x02013;0.36). Likewise, in the fully adjusted model, RAR was positively correlated with NLR (&#x003b2;&#x02009;=&#x02009;0.39, 95% CI: 0.36&#x02013;0.42). Subsequently, multivariate Cox regression analyses were performed to examine the associations between SIRI, NLR, and all-cause mortality. Results indicated that in the fully adjusted model, SIRI was positively associated with all-cause mortality (HR&#x02009;=&#x02009;1.19, 95% CI: 1.17&#x02013;1.20), as was NLR (HR&#x02009;=&#x02009;1.12, 95% CI: 1.11&#x02013;1.14). Finally, mediation effect analyses (<xref rid="pone.0324027.g004" ref-type="fig">Fig 4</xref> and <xref rid="pone.0324027.t004" ref-type="table">Table 4</xref>) revealed that, after adjusting for all covariates, the relationship between RAR and all-cause mortality was mediated by SIRI and NLR by approximately 8.12% and 6.00%, respectively. Additionally, other inflammatory markers, including the aggregate index of systemic inflammation (AISI), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), exhibited partial mediation when analyzed for mediating effects (<xref rid="pone.0324027.s005" ref-type="supplementary-material">S3 Table</xref>).</p><table-wrap position="float" id="pone.0324027.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.t004</object-id><label>Table 4</label><caption><title>The mediating role of SIRI and NLR in the association between RAR and all-cause mortality.</title></caption><alternatives><graphic xlink:href="pone.0324027.t004" id="pone.0324027.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Mediation effect</th><th align="left" rowspan="1" colspan="1">Estimate</th><th align="left" rowspan="1" colspan="1">95% CI lower</th><th align="left" rowspan="1" colspan="1">95% CI upper</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>SIRI</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total effect</td><td align="left" rowspan="1" colspan="1">131.43</td><td align="left" rowspan="1" colspan="1">119.49</td><td align="left" rowspan="1" colspan="1">144.43</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Mediation effect</td><td align="left" rowspan="1" colspan="1">10.73</td><td align="left" rowspan="1" colspan="1">9.07</td><td align="left" rowspan="1" colspan="1">12.57</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Direct effect</td><td align="left" rowspan="1" colspan="1">122.57</td><td align="left" rowspan="1" colspan="1">110.76</td><td align="left" rowspan="1" colspan="1">135.11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Proportion mediated</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>NLR</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total effect</td><td align="left" rowspan="1" colspan="1">136.92</td><td align="left" rowspan="1" colspan="1">124.72</td><td align="left" rowspan="1" colspan="1">150.23</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Mediation effect</td><td align="left" rowspan="1" colspan="1">8.27</td><td align="left" rowspan="1" colspan="1">6.97</td><td align="left" rowspan="1" colspan="1">9.67</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Direct effect</td><td align="left" rowspan="1" colspan="1">128.65</td><td align="left" rowspan="1" colspan="1">116.59</td><td align="left" rowspan="1" colspan="1">141.31</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Proportion mediated</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Age, gender, race, body mass index, education, marital status, PIR, hypercholesterolemia, diabetes, alcohol consumption, vigorous activity, moderate activity, cardiovascular disease, smoking were adjusted.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="pone.0324027.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0324027.g004</object-id><label>Fig 4</label><caption><title>Role of SIRI and NLR in the association between RAR and all-cause mortality.</title><p>(A) Mediation analysis of the association between RAR and all-cause mortality by SlRl. (B) Mediation analysis of the association between RAR and all-cause mortality by NLR.</p></caption><graphic xlink:href="pone.0324027.g004" position="float"/></fig></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>This study investigated the association between the red cell distribution width to albumin ratio (RAR) and mortality in hypertensive individuals, with a particular focus on the mediating role of inflammatory markers. Our findings revealed that higher RAR values were significantly associated with increased mortality. Notably, the strength of this association was more pronounced when RAR values were below 4.1.</p><p>These findings align with prior studies demonstrating the prognostic significance of RDW and albumin levels in chronic diseases [<xref rid="pone.0324027.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0324027.ref009" ref-type="bibr">9</xref>]. RDW, a marker of red cell heterogeneity, is associated with oxidative stress and systemic inflammation, while hypoalbuminemia reflects malnutrition and an ongoing inflammatory state. By integrating these two markers, RAR provides a more comprehensive reflection of the inflammatory and nutritional status of individuals.</p><p>Inflammation appears to be a pivotal mechanism linking RAR to mortality in hypertensive individuals. Chronic low-grade inflammation is a well-established contributor to the pathophysiology of cardiovascular and metabolic diseases, as it drives processes such as endothelial dysfunction, vascular remodeling, and atherosclerosis [<xref rid="pone.0324027.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0324027.ref014" ref-type="bibr">14</xref>]. In our study, the SIRI and NLRmediated 8.12% and 6.00% of the association between RAR and all-cause mortality, respectively. These findings underscore the partial but significant role of systemic inflammation in amplifying mortality risk among hypertensive patients [<xref rid="pone.0324027.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324027.ref015" ref-type="bibr">15</xref>].</p><p>Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are frequently elevated in hypertensive individuals and play critical roles in this context [<xref rid="pone.0324027.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0324027.ref017" ref-type="bibr">17</xref>]. CRP is an acute-phase protein that reflects systemic inflammation and directly contributes to endothelial dysfunction by inhibiting nitric oxide production, increasing oxidative stress, and promoting vascular stiffness [<xref rid="pone.0324027.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0324027.ref019" ref-type="bibr">19</xref>]. Similarly, IL-6 acts as both a pro-inflammatory cytokine and a regulator of acute-phase responses, exacerbating vascular inflammation and contributing to arterial plaque instability. These processes may lead to vasoconstriction, increased thrombogenesis, and elevated blood pressure, creating a self-perpetuating cycle of inflammation and vascular injury [<xref rid="pone.0324027.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0324027.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0324027.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0324027.ref021" ref-type="bibr">21</xref>].</p><p>Moreover, inflammation can impair metabolic homeostasis by influencing lipid metabolism and reducing insulin sensitivity. Elevated inflammatory cytokines have been shown to increase lipolysis, promote the formation of oxidized low-density lipoproteins (ox-LDL), and impair glucose uptake in peripheral tissues. For instance, the presence of inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha has been positively correlated with metabolic disturbances, including insulin resistance and dyslipidemia, which are critical factors in the pathogenesis of cardiovascular diseases [<xref rid="pone.0324027.ref022" ref-type="bibr">22</xref>]. Additionally, macrophages, which play a crucial role in atherosclerosis, can ingest ox-LDL, leading to foam cell formation&#x02014;a hallmark of atherosclerotic plaques [<xref rid="pone.0324027.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0324027.ref024" ref-type="bibr">24</xref>]. This process is exacerbated by the inflammatory environment, which further promotes lipid metabolism disorders and insulin resistance [<xref rid="pone.0324027.ref025" ref-type="bibr">25</xref>].</p><p>These metabolic derangements not only worsen the cardiovascular risk profile of hypertensive patients but may also directly contribute to the observed association between the erythrocyte distribution width-to-albumin ratio (RAR) and mortality. RAR has been identified as a potential prognostic marker in various cardiovascular conditions, including heart failure and diabetic complications [<xref rid="pone.0324027.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0324027.ref026" ref-type="bibr">26</xref>]. Studies have shown that elevated RAR levels correlate with increased mortality rates, suggesting that inflammation and metabolic dysregulation may mediate this relationship [<xref rid="pone.0324027.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0324027.ref028" ref-type="bibr">28</xref>]. Furthermore, the inflammatory milieu associated with atherosclerosis can lead to increased production of pro-inflammatory cytokines and reactive oxygen species, which in turn can impair glucose metabolism and exacerbate cardiovascular risks [<xref rid="pone.0324027.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0324027.ref030" ref-type="bibr">30</xref>]. Thus, the interplay between inflammation, lipid metabolism, and insulin sensitivity is critical in understanding the mechanisms linking RAR to mortality in hypertensive patients.</p><p>The observed threshold effect indicates a nonlinear association between RAR and mortality, with a higher hazard ratio (HR) when RAR is below 4.10 compared to when it exceeds 4.10. In hypertensive patients with RAR&#x02009;&#x0003e;&#x02009;4.10 (higher RAR group), this may indicate that inflammatory trophic homeostasis has entered a decompensation phase, where predominant end-stage events (e.g., sudden cardiac death, multi-organ failure) could obscure RAR&#x02019;s independent effect amid a worsened physiological state. Nevertheless, additional mechanistic studies are required to elucidate this association. Monitoring RAR levels could aid in stratifying patients based on their mortality risk and guiding targeted interventions. Reducing RAR values may mitigate inflammation, improving vascular health and overall prognosis.</p><p>Despite its strengths, this study has several limitations. First, the retrospective design may have introduced selection bias, limiting causal inferences. Although we adjusted for multiple potential confounders, residual confounding from unmeasured factors, such as socioeconomic status or specific treatment regimens, cannot be excluded. Second, while NHANES data are representative of the U.S. population, their applicability to other regions or ethnic groups may be limited.</p><p>Future research should confirm these findings across diverse populations, including hypertensive patients from various regions and with differing comorbidities, to assess RAR&#x02019;s generalizability as a prognostic biomarker. Longitudinal and repeated-measures studies with extended follow-up are also required to clarify the causal links between RAR, inflammation, and mortality. The threshold effect at RAR&#x02009;=&#x02009;4.10 necessitates additional molecular biology studies to uncover the underlying mechanisms. Lastly, clinical trials assessing the efficacy of anti-inflammatory interventions in patients with elevated RAR levels could yield valuable insights into strategies for improving prognosis in this high-risk group.</p></sec><sec sec-type="conclusions" id="sec019"><title>Conclusions</title><p>In hypertensive populations, elevated RAR values are associated with increased all-cause, cardiovascular, and cancer-related mortality. Systemic inflammation partially mediates the relationship between RAR and all-cause mortality, highlighting its role as a potential link between nutritional status, inflammation, and adverse outcomes.</p></sec><sec id="sec020" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0324027.s001" position="float" content-type="local-data"><label>S1 Raw data</label><caption><title>Original data for this study.</title><p>(CSV)</p></caption><media xlink:href="pone.0324027.s001.csv"/></supplementary-material><supplementary-material id="pone.0324027.s002" position="float" content-type="local-data"><label>S1 File</label><caption><title>Threshold and saturation effect analysis explained.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324027.s002.docx"/></supplementary-material><supplementary-material id="pone.0324027.s003" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Association of RAR with mortality in the population.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324027.s003.docx"/></supplementary-material><supplementary-material id="pone.0324027.s004" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Subgroup Analysis of the Relationship Between RAR and Mortality by Age.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324027.s004.docx"/></supplementary-material><supplementary-material id="pone.0324027.s005" position="float" content-type="local-data"><label>S3 Table</label><caption><title>Mediating role of other inflammatory markers in the association between RAR and all-cause mortality.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324027.s005.docx"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0324027.ref001"><label>1</label><mixed-citation publication-type="journal"><collab>GBD 2019 Stroke Collaborators</collab>. <article-title>Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Neurol</source>. <year>2021</year>;<volume>20</volume>(<issue>10</issue>):<fpage>795</fpage>&#x02013;<lpage>820</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00252-0</pub-id>
<pub-id pub-id-type="pmid">34487721</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Franco</surname><given-names>C</given-names></name>, <name><surname>Sciatti</surname><given-names>E</given-names></name>, <name><surname>Favero</surname><given-names>G</given-names></name>, <name><surname>Bonomini</surname><given-names>F</given-names></name>, <name><surname>Vizzardi</surname><given-names>E</given-names></name>, <name><surname>Rezzani</surname><given-names>R</given-names></name>. <article-title>Essential hypertension and oxidative stress: novel future perspectives</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>22</issue>).</mixed-citation></ref><ref id="pone.0324027.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>D</given-names></name>, <name><surname>Xi</surname><given-names>B</given-names></name>, <name><surname>Zhao</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Veeranki</surname><given-names>SP</given-names></name>. <article-title>Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>9418</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-018-27377-2</pub-id>
<pub-id pub-id-type="pmid">29925884</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>Y</given-names></name>, <name><surname>Xiao</surname><given-names>F</given-names></name>, <name><surname>Luo</surname><given-names>Q</given-names></name>, <name><surname>Liao</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>He</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Red cell distribution width to albumin ratio predicts treatment failure in peritoneal dialysis-associated peritonitis</article-title>. <source>Ther Apher Dial</source>. <year>2024</year>;<volume>28</volume>(<issue>3</issue>):<fpage>399</fpage>&#x02013;<lpage>408</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1744-9987.14098</pub-id>
<pub-id pub-id-type="pmid">38112028</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Gao</surname><given-names>TY</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>SN</given-names></name>, <name><surname>Xu</surname><given-names>YY</given-names></name>, <etal>et al</etal>. <article-title>Red blood cell distribution width to albumin ratio associates with prevalence and long-term diabetes mellitus prognosis: an overview of NHANES 1999-2020 data</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2024</year>;<volume>15</volume>:<fpage>1362077</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fendo.2024.1362077</pub-id>
<pub-id pub-id-type="pmid">39114290</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Long</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>He</surname><given-names>M</given-names></name>, <name><surname>Zeng</surname><given-names>Q</given-names></name>, <name><surname>He</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Association between red cell distribution width-and-albumin ratio and the risk of peripheral artery disease in patients with diabetes</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2024</year>;<volume>15</volume>:<fpage>1272573</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fendo.2024.1272573</pub-id>
<pub-id pub-id-type="pmid">38405142</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Hao</surname><given-names>M</given-names></name>, <name><surname>Jiang</surname><given-names>S</given-names></name>, <name><surname>Tang</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Ratio of red blood cell distribution width to albumin level and risk of mortality</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>(<issue>5</issue>):e2413213. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.13213</pub-id>
<pub-id pub-id-type="pmid">38805227</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Lu</surname><given-names>S</given-names></name>, <name><surname>Kang</surname><given-names>T</given-names></name>, <name><surname>Meng</surname><given-names>F</given-names></name>, <name><surname>Qian</surname><given-names>T</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Red cell distribution width/albumin ratio and mortality risk in rheumatoid arthritis patients: Insights from a NHANES study</article-title>. <source>Int J Rheum Dis</source>. <year>2024</year>;<volume>27</volume>(<issue>9</issue>):e15335. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1756-185X.15335</pub-id>
<pub-id pub-id-type="pmid">39278721</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Hu</surname><given-names>F</given-names></name>, <name><surname>Xu</surname><given-names>C</given-names></name>. <article-title>Association between red blood cell distribution width/albumin ratio and all-cause mortality or cardiovascular diseases mortality in patients with diabetic retinopathy: a cohort study</article-title>. <source>PLoS One</source>. <year>2023</year>;<volume>18</volume>(<issue>12</issue>):e0296019. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0296019</pub-id>
<pub-id pub-id-type="pmid">38128055</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Miao</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>Q</given-names></name>. <article-title>Red cell distribution width/albumin ratio as a marker for metabolic syndrome: findings from a cross-sectional study</article-title>. <source>BMC Endocr Disord</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>227</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12902-024-01762-7</pub-id>
<pub-id pub-id-type="pmid">39455980</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Dziedzic</surname><given-names>EA</given-names></name>, <name><surname>G&#x00105;sior</surname><given-names>JS</given-names></name>, <name><surname>Tuzimek</surname><given-names>A</given-names></name>, <name><surname>Paleczny</surname><given-names>J</given-names></name>, <name><surname>Junka</surname><given-names>A</given-names></name>, <name><surname>D&#x00105;browski</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Investigation of the associations of novel inflammatory biomarkers-systemic inflammatory index (SII) and systemic inflammatory response index (SIRI)-with the severity of coronary artery disease and acute coronary syndrome occurrence</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>17</issue>).</mixed-citation></ref><ref id="pone.0324027.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Cheang</surname><given-names>I</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Yue</surname><given-names>X</given-names></name>, <name><surname>Tang</surname><given-names>Y</given-names></name>, <name><surname>Gao</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Associations of inflammation with risk of cardiovascular and all-cause mortality in adults with hypertension: an inflammatory prognostic scoring system</article-title>. <source>J Inflamm Res</source>. <year>2022</year>;<volume>15</volume>:<fpage>6125</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/JIR.S384977</pub-id>
<pub-id pub-id-type="pmid">36386589</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Paulus</surname><given-names>WJ</given-names></name>, <name><surname>Tsch&#x000f6;pe</surname><given-names>C</given-names></name>. <article-title>A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>(<issue>4</issue>):<fpage>263</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.092</pub-id>
<pub-id pub-id-type="pmid">23684677</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Gao</surname><given-names>Z</given-names></name>, <name><surname>Bao</surname><given-names>T</given-names></name>, <name><surname>Dong</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction</article-title>. <source>Cell Commun Signal</source>. <year>2023</year>;<volume>21</volume>(<issue>1</issue>):<fpage>298</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12964-022-01016-w</pub-id>
<pub-id pub-id-type="pmid">37904236</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Zuo</surname><given-names>R</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Association of systemic immune inflammation index with all-cause, cardiovascular disease, and cancer-related mortality in patients with cardiovascular disease: a cross-sectional study</article-title>. <source>J Inflamm Res</source>. <year>2023</year>;<volume>16</volume>:<fpage>941</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/JIR.S402227</pub-id>
<pub-id pub-id-type="pmid">36908696</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Jiang</surname><given-names>P</given-names></name>, <name><surname>Kang</surname><given-names>R</given-names></name>, <name><surname>Xie</surname><given-names>Y</given-names></name>. <article-title>Correlation between hs-CRP, IL-6, IL-10, ET-1, and chronic obstructive pulmonary disease combined with pulmonary hypertension</article-title>. <source>J Healthc Eng</source>. <year>2022</year>;<volume>2022</volume>:<fpage>3247807</fpage>.<pub-id pub-id-type="pmid">35186226</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Sulicka-Grodzicka</surname><given-names>J</given-names></name>, <name><surname>Wizner</surname><given-names>B</given-names></name>, <name><surname>Zdrojewski</surname><given-names>T</given-names></name>, <name><surname>Mossakowska</surname><given-names>M</given-names></name>, <name><surname>Puzianowska-Ku&#x0017a;nicka</surname><given-names>M</given-names></name>, <name><surname>Chudek</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Sex-specific relationships of inflammatory biomarkers with blood pressure in older adults</article-title>. <source>Geroscience</source>. <year>2024</year>;<volume>46</volume>(<issue>5</issue>):<fpage>4603</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11357-024-01170-8</pub-id>
<pub-id pub-id-type="pmid">38720047</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Murdaca</surname><given-names>G</given-names></name>, <name><surname>Span&#x000f2;</surname><given-names>F</given-names></name>, <name><surname>Cagnati</surname><given-names>P</given-names></name>, <name><surname>Puppo</surname><given-names>F</given-names></name>. <article-title>Free radicals and endothelial dysfunction: potential positive effects of TNF-&#x003b1; inhibitors</article-title>. <source>Redox Rep</source>. <year>2013</year>;<volume>18</volume>(<issue>3</issue>):<fpage>95</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1179/1351000213Y.0000000046</pub-id>
<pub-id pub-id-type="pmid">23676793</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Zaib</surname><given-names>S</given-names></name>, <name><surname>Ahmad</surname><given-names>S</given-names></name>, <name><surname>Khan</surname><given-names>I</given-names></name>, <name><surname>Bin Jardan</surname><given-names>YA</given-names></name>, <name><surname>Fentahun Wondmie</surname><given-names>G</given-names></name>. <article-title>An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>15348</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-024-65188-w</pub-id>
<pub-id pub-id-type="pmid">38961103</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Toshner</surname><given-names>M</given-names></name>, <name><surname>Rothman</surname><given-names>A</given-names></name>. <article-title>IL-6 in pulmonary hypertension: why novel is not always best</article-title>. <source>Eur Respir J</source>
<year>2020</year>;<volume>55</volume>(<issue>4</issue>).</mixed-citation></ref><ref id="pone.0324027.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Tang</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <name><surname>Xie</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Dong</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling</article-title>. <source>Free Radic Biol Med</source>. <year>2022</year>;<volume>181</volume>:<fpage>130</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.01.020</pub-id>
<pub-id pub-id-type="pmid">35122997</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Cho</surname><given-names>Y-H</given-names></name>, <name><surname>Lee</surname><given-names>Y</given-names></name>, <name><surname>Choi</surname><given-names>JI</given-names></name>, <name><surname>Lee</surname><given-names>SR</given-names></name>, <name><surname>Lee</surname><given-names>SY</given-names></name>. <article-title>Biomarkers in metabolic syndrome</article-title>. <source>Adv Clin Chem</source>. <year>2022</year>;<volume>111</volume>:<fpage>101</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/bs.acc.2022.07.003</pub-id>
<pub-id pub-id-type="pmid">36427908</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Kang</surname><given-names>Y</given-names></name>, <name><surname>Pan</surname><given-names>W</given-names></name>, <name><surname>Lei</surname><given-names>W</given-names></name>, <name><surname>Feng</surname><given-names>B</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>Enhancement of anti-inflammatory activity of curcumin using phosphatidylserine-containing nanoparticles in cultured macrophages</article-title>. <source>Int J Mol Sci</source>. <year>2016</year>;<volume>17</volume>(<issue>5</issue>).</mixed-citation></ref><ref id="pone.0324027.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kattoor</surname><given-names>AJ</given-names></name>, <name><surname>Goel</surname><given-names>A</given-names></name>, <name><surname>Mehta</surname><given-names>JL</given-names></name>. <article-title>LOX-1: regulation, signaling and its role in atherosclerosis</article-title>. <source>Antioxidants (Basel)</source>. <year>2019</year>;<volume>8</volume>(<issue>7</issue>):<fpage>218</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/antiox8070218</pub-id>
<pub-id pub-id-type="pmid">31336709</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Shin</surname><given-names>KC</given-names></name>, <name><surname>Hwang</surname><given-names>I</given-names></name>, <name><surname>Choe</surname><given-names>SS</given-names></name>, <name><surname>Park</surname><given-names>J</given-names></name>, <name><surname>Ji</surname><given-names>Y</given-names></name>, <name><surname>Kim</surname><given-names>JI</given-names></name>, <etal>et al</etal>. <article-title>Macrophage VLDLR mediates obesity-induced insulin resistance with adipose tissue inflammation</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1087</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-017-01232-w</pub-id>
<pub-id pub-id-type="pmid">29057873</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Y-L</given-names></name>, <name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Huang</surname><given-names>Z-B</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Dai</surname><given-names>Z-S</given-names></name>. <article-title>Relationship between red blood cell distribution width-to-albumin ratio and outcome of septic patients with atrial fibrillation: a retrospective cohort study</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>538</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12872-022-02975-1</pub-id>
<pub-id pub-id-type="pmid">36494633</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>W</given-names></name>, <name><surname>Huo</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>G</given-names></name>, <name><surname>Yang</surname><given-names>K</given-names></name>, <name><surname>Huang</surname><given-names>Z</given-names></name>, <name><surname>Peng</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Association between red blood cell distribution width to albumin ratio and prognosis of patients with sepsis: a retrospective cohort study</article-title>. <source>Front Nutr</source>. <year>2022</year>;<volume>9</volume>:<fpage>1019502</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnut.2022.1019502</pub-id>
<pub-id pub-id-type="pmid">36211519</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Cai</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Luo</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Relationship between the ratio of red cell distribution width to albumin and 28-day mortality among Chinese patients over 80 years with atrial fibrillation</article-title>. <source>Gerontology</source>. <year>2023</year>;<volume>69</volume>(<issue>12</issue>):<fpage>1471</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1159/000534259</pub-id>
<pub-id pub-id-type="pmid">37793355</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Ou</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>Z</given-names></name>, <name><surname>Mo</surname><given-names>Z</given-names></name>, <name><surname>Xiao</surname><given-names>J</given-names></name>. <article-title>The characteristics and roles of advanced oxidation protein products in atherosclerosis</article-title>. <source>Cardiovasc Toxicol</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s12012-016-9377-8</pub-id>
<pub-id pub-id-type="pmid">27350146</pub-id>
</mixed-citation></ref><ref id="pone.0324027.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Weintraub</surname><given-names>NL</given-names></name>, <name><surname>Rubinstein</surname><given-names>J</given-names></name>. <article-title>Cooling the fire of atherosclerosis with heat shock protein 27</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>(<issue>16</issue>):<fpage>1455</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacc.2013.05.040</pub-id>
<pub-id pub-id-type="pmid">23747762</pub-id>
</mixed-citation></ref></ref-list></back></article>